EPCAM and neoplasm: Mesenchymal CD44+/CD24−/low CSCs do not express E-cadherin but gain further tumor initiating capacity with the expression of the epithelial adhesion molecule EpCAM that marks “hybrid E/M” states (Dittmer, 2018).